Artificial Liver Support Systems in Acute Liver Failure and Acute-on-Chronic Liver Failure: Systematic Review and Meta-Analysis

OBJECTIVES:. To systematically review the safety and efficacy of nonbiological (NBAL) or biological artificial liver support systems (BAL) and whole-organ extracorporeal liver perfusion (W-ECLP) systems, in adults with acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). DATA SOURCES...

Full description

Saved in:
Bibliographic Details
Main Authors: Robert S. Brown, Jr, MD, MPH, Robert A. Fisher, MD, FACS, TACC, Ram M. Subramanian, MD, MBA, Adam Griesemer, MD, Milene Fernandes, PharmD, MSc, William H. Thatcher, MS, Kathryn Stiede, BS, Michael Curtis, PhD
Format: Article
Language:English
Published: Wolters Kluwer 2025-01-01
Series:Critical Care Explorations
Online Access:http://journals.lww.com/10.1097/CCE.0000000000001199
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832589676175687680
author Robert S. Brown, Jr, MD, MPH
Robert A. Fisher, MD, FACS, TACC
Ram M. Subramanian, MD, MBA
Adam Griesemer, MD
Milene Fernandes, PharmD, MSc
William H. Thatcher, MS
Kathryn Stiede, BS
Michael Curtis, PhD
author_facet Robert S. Brown, Jr, MD, MPH
Robert A. Fisher, MD, FACS, TACC
Ram M. Subramanian, MD, MBA
Adam Griesemer, MD
Milene Fernandes, PharmD, MSc
William H. Thatcher, MS
Kathryn Stiede, BS
Michael Curtis, PhD
author_sort Robert S. Brown, Jr, MD, MPH
collection DOAJ
description OBJECTIVES:. To systematically review the safety and efficacy of nonbiological (NBAL) or biological artificial liver support systems (BAL) and whole-organ extracorporeal liver perfusion (W-ECLP) systems, in adults with acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). DATA SOURCES:. Eligible NBAL/BAL studies from PubMed/Embase searches were randomized controlled trials (RCTs) in adult patients with ALF/ACLF, greater than or equal to ten patients per group, reporting outcomes related to survival, adverse events, transplantation rate, and hepatic encephalopathy, and published in English from January 2000 to July 2023. Separately, we searched for studies evaluating W-ECLP in adult patients with ALF or ACLF published between January1990 and July 2023. STUDY SELECTION AND DATA EXTRACTION:. Two researchers independently screened citations for eligibility and, of eligible studies, retrieved data related to study characteristics, patients and interventions, outcomes definition, and intervention effects. The Cochrane Risk of Bias 2 tool and Joanna Briggs Institute checklists were used to assess individual study risk of bias. Meta-analysis of mortality at 28–30 days post-support system initiation and frequency of at least one serious adverse event (SAE) generated pooled risk ratios (RRs), based on random (mortality) or fixed (SAE) effects models. DATA SYNTHESIS:. Of 17 trials evaluating NBAL/BAL systems, 11 reported 28–30 days mortality and five reported frequency of at least one SAE. Overall, NBAL/BAL was not statistically associated with mortality at 28–30 days (RR, 0.85; 95% CI, 0.67–1.07; p = 0.169) or frequency of at least one SAE (RR, 1.15; 95% CI, 0.99–1.33; p = 0.059), compared with standard medical treatment. Subgroup results on ALF patients suggest possible benefit for mortality (RR, 0.67; 95% CI, 0.44–1.03; p = 0.069). From six reports of W-ECLP (12 patients), more than half (58%) of severe patients were bridged to transplantation and survived without transmission of porcine retroviruses. CONCLUSIONS:. Despite no significant pooled effects of NBAL/BAL devices, the available evidence calls for further research and development of extracorporeal liver support systems, with larger RCTs and optimization of patient selection, perfusion durability, and treatment protocols.
format Article
id doaj-art-078b588f994b41f39f07f037605021c5
institution Kabale University
issn 2639-8028
language English
publishDate 2025-01-01
publisher Wolters Kluwer
record_format Article
series Critical Care Explorations
spelling doaj-art-078b588f994b41f39f07f037605021c52025-01-24T09:19:27ZengWolters KluwerCritical Care Explorations2639-80282025-01-0171e119910.1097/CCE.0000000000001199202501000-00003Artificial Liver Support Systems in Acute Liver Failure and Acute-on-Chronic Liver Failure: Systematic Review and Meta-AnalysisRobert S. Brown, Jr, MD, MPH0Robert A. Fisher, MD, FACS, TACC1Ram M. Subramanian, MD, MBA2Adam Griesemer, MD3Milene Fernandes, PharmD, MSc4William H. Thatcher, MS5Kathryn Stiede, BS6Michael Curtis, PhD71 Center for Liver Disease, Weill Cornell Medicine, New York, NY.2 CTI Clinical Trial and Consulting Services, Covington, KY.3 Hepatology and Critical Care, Emory University, Atlanta, GA.4 NYU Langone Health, New York, NY.2 CTI Clinical Trial and Consulting Services, Covington, KY.2 CTI Clinical Trial and Consulting Services, Covington, KY.5 eGenesis, Inc., Cambridge, MA.5 eGenesis, Inc., Cambridge, MA.OBJECTIVES:. To systematically review the safety and efficacy of nonbiological (NBAL) or biological artificial liver support systems (BAL) and whole-organ extracorporeal liver perfusion (W-ECLP) systems, in adults with acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). DATA SOURCES:. Eligible NBAL/BAL studies from PubMed/Embase searches were randomized controlled trials (RCTs) in adult patients with ALF/ACLF, greater than or equal to ten patients per group, reporting outcomes related to survival, adverse events, transplantation rate, and hepatic encephalopathy, and published in English from January 2000 to July 2023. Separately, we searched for studies evaluating W-ECLP in adult patients with ALF or ACLF published between January1990 and July 2023. STUDY SELECTION AND DATA EXTRACTION:. Two researchers independently screened citations for eligibility and, of eligible studies, retrieved data related to study characteristics, patients and interventions, outcomes definition, and intervention effects. The Cochrane Risk of Bias 2 tool and Joanna Briggs Institute checklists were used to assess individual study risk of bias. Meta-analysis of mortality at 28–30 days post-support system initiation and frequency of at least one serious adverse event (SAE) generated pooled risk ratios (RRs), based on random (mortality) or fixed (SAE) effects models. DATA SYNTHESIS:. Of 17 trials evaluating NBAL/BAL systems, 11 reported 28–30 days mortality and five reported frequency of at least one SAE. Overall, NBAL/BAL was not statistically associated with mortality at 28–30 days (RR, 0.85; 95% CI, 0.67–1.07; p = 0.169) or frequency of at least one SAE (RR, 1.15; 95% CI, 0.99–1.33; p = 0.059), compared with standard medical treatment. Subgroup results on ALF patients suggest possible benefit for mortality (RR, 0.67; 95% CI, 0.44–1.03; p = 0.069). From six reports of W-ECLP (12 patients), more than half (58%) of severe patients were bridged to transplantation and survived without transmission of porcine retroviruses. CONCLUSIONS:. Despite no significant pooled effects of NBAL/BAL devices, the available evidence calls for further research and development of extracorporeal liver support systems, with larger RCTs and optimization of patient selection, perfusion durability, and treatment protocols.http://journals.lww.com/10.1097/CCE.0000000000001199
spellingShingle Robert S. Brown, Jr, MD, MPH
Robert A. Fisher, MD, FACS, TACC
Ram M. Subramanian, MD, MBA
Adam Griesemer, MD
Milene Fernandes, PharmD, MSc
William H. Thatcher, MS
Kathryn Stiede, BS
Michael Curtis, PhD
Artificial Liver Support Systems in Acute Liver Failure and Acute-on-Chronic Liver Failure: Systematic Review and Meta-Analysis
Critical Care Explorations
title Artificial Liver Support Systems in Acute Liver Failure and Acute-on-Chronic Liver Failure: Systematic Review and Meta-Analysis
title_full Artificial Liver Support Systems in Acute Liver Failure and Acute-on-Chronic Liver Failure: Systematic Review and Meta-Analysis
title_fullStr Artificial Liver Support Systems in Acute Liver Failure and Acute-on-Chronic Liver Failure: Systematic Review and Meta-Analysis
title_full_unstemmed Artificial Liver Support Systems in Acute Liver Failure and Acute-on-Chronic Liver Failure: Systematic Review and Meta-Analysis
title_short Artificial Liver Support Systems in Acute Liver Failure and Acute-on-Chronic Liver Failure: Systematic Review and Meta-Analysis
title_sort artificial liver support systems in acute liver failure and acute on chronic liver failure systematic review and meta analysis
url http://journals.lww.com/10.1097/CCE.0000000000001199
work_keys_str_mv AT robertsbrownjrmdmph artificialliversupportsystemsinacuteliverfailureandacuteonchronicliverfailuresystematicreviewandmetaanalysis
AT robertafishermdfacstacc artificialliversupportsystemsinacuteliverfailureandacuteonchronicliverfailuresystematicreviewandmetaanalysis
AT rammsubramanianmdmba artificialliversupportsystemsinacuteliverfailureandacuteonchronicliverfailuresystematicreviewandmetaanalysis
AT adamgriesemermd artificialliversupportsystemsinacuteliverfailureandacuteonchronicliverfailuresystematicreviewandmetaanalysis
AT milenefernandespharmdmsc artificialliversupportsystemsinacuteliverfailureandacuteonchronicliverfailuresystematicreviewandmetaanalysis
AT williamhthatcherms artificialliversupportsystemsinacuteliverfailureandacuteonchronicliverfailuresystematicreviewandmetaanalysis
AT kathrynstiedebs artificialliversupportsystemsinacuteliverfailureandacuteonchronicliverfailuresystematicreviewandmetaanalysis
AT michaelcurtisphd artificialliversupportsystemsinacuteliverfailureandacuteonchronicliverfailuresystematicreviewandmetaanalysis